ÀÇ·á¹ýÀÎ ÀÌ¿øÀÇ·áÀç´Ü  

Àç´Ü¼Ò½Ä

Á¦¸ñ ÀÌ¿ø, ±ÇâÇõ ¹Ú»ç ³í¹® °ÔÀç
÷ºÎÆÄÀÏ ÀÛ¼ºÀÏ 2020-12-21

ÀÌ¿ø, ±ÇâÇõ ¹Ú»ç ³í¹® °ÔÀç


   
 ¢ºBBRC, 2020 May 28;526(2):539-545                           ¢ºAdipocyte. 2020 Dec;9(1):576-586     

ÀÌ¿ø ±ÇâÇõ ¹Ú»ç ³í¹® °ÔÀç : BBRC(Biochemical and Biophysical Research Communications), 2020 May 28;526(2):539-545 
ÀÌ¿øÀÇ·áÀç´ÜÀÇ »ý¹°Á¤º¸¼¾ÅÍ ±ÇâÇõ ¹Ú»ç°¡ Á¦1ÀúÀÚ·Î ÀÛ¾÷ÇÏ°í Áß¾Ó´ëÇб³ Á¤ÅÂ¿ì ±³¼ö°¡ ±³½ÅÀúÀÚ·Î Á¦ÃâÇÑ "Humanin attenuates palmitate-induced hepatic lipid accumulation and insulin resistance via AMPK-mediated suppression of the mTOR pathway" ³í¹®ÀÌ BBRC (Biochemical and Biophysical Research Communications) Àú³Î¿¡ °ÔÀçµÇ¾ú½À´Ï´Ù.

ÈçÈ÷ ºñ ¾ËÄݼº Áö¹æ°£ Áúȯ(NAFLD)ÀÇ ¹ßº´±âÀüÀº Àß ¾Ë·ÁÁöÁö ¾Ê¾Ò´Âµ¥, º» ³í¹®¿¡¼­´Â °£¼¼Æ÷ÀÇ ÁöÁú ÃàÀû°ú Àν¶¸° ½ÅÈ£¿¡ ´ëÇÑ Humanin¿¡ ´ëÇÑ È¿°ú¿Í ¸ÞÄ¿´ÏÁòÀ» ¿¬±¸ÇÏ¿´½À´Ï´Ù. HumaninÀº mTOR/SREBP1 °æ·ÎÀÇ AMPK ¸Å°³ ¾ïÁ¦¸¦ ÅëÇØ ÆȹÌÅ×ÀÌÆ®(palmitate)°¡ À¯µµµÇ¾î °£ ÁöÁú ÃàÀû, ¼¼Æ÷ »ç¸ê ¹× Àν¶¸° ÀúÇ×¼ºÀ» ¿¹¹æÇÏ¿© NAFLD Ä¡·á¿¡¼­ ÀáÀçÀûÀÎ Ä¡·áÁ¦·Î ÀÛ¿ëÇÒ ¼ö ÀÖÀ½À» ¹àÇû½À´Ï´Ù.

ÀÌ¿ø ±ÇâÇõ ¹Ú»ç ³í¹® °ÔÀç : Adipocyte. 2020 Dec;9(1):576-586 
ÀÌ¿øÀÇ·áÀç´Ü »ý¹°Á¤º¸¼¾ÅÍ ±ÇâÇõ ¹Ú»ç°¡ Á¦1ÀúÀÚ·Î Âü¿©ÇÏ°í, Áß¾Ó´ëÇб³ Á¤ÅÂ¿ì ±³¼ö°¡ ±³½ÅÀúÀÚ·Î Á¦ÃâÇÑ "Clinically confirmed DEL-1 as a myokine attenuates lipid-induced inflammation and insulin resistance in 3T3-L1 adipocytes via AMPK/HO-1- pathway" ³í¹®ÀÌ Adipocyte Àú³Î¿¡ °ÔÀçµÇ¾ú½À´Ï´Ù.

º» ³í¹®¿¡¼­´Â DEL-1 À¯ÀüÀÚ´Â ´ë½Ä¼¼Æ÷¸¦ Áõ°¡½ÃÄÑ ¿°Áõ Á¦°Å¸¦ À¯¹ßÇÒ»Ó¸¸ ¾Æ´Ï¶ó °ñ°Ý±ÙÀÇ Àν¶¸° ÀúÇ×¼ºÀ» Çâ»ó½ÃÅ°´Â °ÍÀ¸·Î º¸°íµÇ¾ú½À´Ï´Ù.
±×·¯³ª DEL-1°ú ¿îµ¿°úÀÇ °ü°è¿Í Áö¹æ¼¼Æ÷¿¡¼­ Àν¶¸° ½ÅÈ£ Àü´ÞÀÇ ¿µÇâÀº ¹àÇôÁöÁö ¾Ê¾Ò½À´Ï´Ù. ´Ù¾çÇÑ ½ÇÇèÀ» ÅëÇÏ¿© DEL-1Àº AMPK/HO-1(haem oxygenase-1) ½ÅÈ£¸¦ ÅëÇØ ¿°Áõ°ú Àν¶¸° ÀúÇ×¼ºÀ» °³¼±ÇÏ¿© Àν¶¸° ÀúÇ×¼º°ú Á¦2Çü ´ç´¢º´À» Ä¡·áÇϱâ À§ÇÑ Ä¡·á Ç¥ÀûÀÌ µÉ ¼ö ÀÖÀ½À» ¹ß°ß ÇÏ¿´½À´Ï´Ù.